Datasets:

xpertsystems
/

hc-end-007-sample

patient_id string	age_at_baseline_years float64	sex string	race_ethnicity string	insurance_type string	geographic_region string	menopause_status string	age_at_menopause_years float64	years_since_menopause float64	height_at_peak_cm float64	current_height_cm float64	height_loss_cm float64	weight_kg float64	bmi_kg_m2 float64	smoking_status string	alcohol_drinks_per_week int64	physical_activity_level string	ses_index float64	peak_bmd_lumbar_g_cm2 float64	bmd_lumbar_spine_g_cm2 float64	bmd_femoral_neck_g_cm2 float64	bmd_total_hip_g_cm2 float64	bmd_forearm_33pct_g_cm2 float64	tscore_lumbar_spine float64	tscore_femoral_neck float64	tscore_total_hip float64	zscore_lumbar_spine float64	zscore_femoral_neck float64	who_category string	trabecular_bone_score float64	bone_loss_rate_pct_yr float64	lifetime_bmd_loss_pct float64	lowest_tscore float64	frax_10yr_major_osteoporotic_pct float64	frax_10yr_hip_pct float64	frax_with_bmd_major_pct float64	frax_with_bmd_hip_pct float64	treatment_indicated_frax_flag int64	prior_fracture_flag int64	prior_fracture_site string	vertebral_fracture_count_baseline int64	prior_fracture_age_years float64	parental_hip_fracture_flag int64	secondary_osteoporosis_flag int64	rheumatoid_arthritis_flag int64	glucocorticoid_use_flag int64	falls_per_year int64	garvan_5yr_any_fracture_pct float64	secondary_cause string	glucocorticoid_dose_mg_pred_equiv float64	glucocorticoid_duration_months int64	acr_giop_risk_category string	25ohd_vitamin_d_ng_ml float64	vitamin_d_status string	1_25ohd_active_pg_ml float64	pth_pg_ml float64	calcium_serum_mg_dl float64	hypercalcemia_flag int64	phosphorus_mg_dl float64	magnesium_mg_dl float64	tsh_mIU_l float64	testosterone_ng_dl float64	male_hypogonadism_flag int64	estradiol_pg_ml float64	fsh_mIU_ml float64	igf1_ng_ml float64	cortisol_am_ug_dl float64	egfr_ml_min_1_73m2 float64	ckd_mineral_bone_disease_flag int64	celiac_antibody_flag int64	spep_m_spike_flag int64	ctx_serum_ng_ml float64	p1np_serum_ug_l float64	osteocalcin_ng_ml float64	bsap_ug_l float64	ntx_urine_nM_BCE_mM_creat float64	sclerostin_pmol_l float64	dkk1_pmol_l float64	rankl_pmol_l float64	opg_pmol_l float64	rankl_opg_ratio float64	btm_remodeling_balance float64	treatment_flag int64	treatment_type string	treatment_duration_years float64	treatment_adherence_pct float64	treatment_gap_years float64	bmd_spine_gain_3yr_pct float64	bmd_hip_gain_3yr_pct float64	fracture_rr_vertebral_on_tx float64	fracture_rr_hip_on_tx float64	drug_holiday_flag int64	drug_holiday_duration_years float64	atypical_femur_fracture_flag int64	sequential_therapy_flag int64	sequential_antiresorptive string	calcium_supplement_mg_day int64	vitamin_d_supplement_IU_day int64	giop_bisphosphonate_flag int64	fall_risk_score float64	fall_risk_category string	tug_test_seconds float64	tug_high_risk_flag int64	chair_stand_30sec int64	grip_strength_kg float64	sarcopenia_grip_flag int64	gait_speed_m_sec float64	low_gait_speed_flag int64	berg_balance_scale int64	berg_fall_risk_flag int64	single_leg_stance_seconds float64	visual_acuity_logmar float64	orthostatic_hypotension_flag int64	polypharmacy_flag int64	muscle_mass_appendicular_kg float64	asmmi_kg_m2 float64	sarcopenia_asmmi_flag int64	home_hazard_score float64	hip_fracture_incident_flag int64	hip_fracture_time_to_event_years float64	vertebral_fracture_incident_flag int64	vertebral_fracture_time_years float64	wrist_fracture_flag int64	humerus_fracture_flag int64	back_pain_vas_0_10 float64	oswestry_disability_index_pct float64	eq5d_utility_score float64	sf36_physical_component float64	sf36_mental_component float64	fear_of_falling_fes_score int64	hip_fx_1yr_mortality_pct float64	depression_flag int64	anxiety_flag int64	fracture_liaison_service_flag int64	rehab_utilization_flag int64	total_healthcare_cost_usd float64	hip_fracture_episode_cost_usd float64	vertebral_fx_episode_cost_usd float64	icd10_primary_code string
HC007-000001	68	Female	Black	Medicare	Urban	Postmenopausal	44	24	166	166	0.1	58.7	21.3	Never	4	Moderate	4.6	0.9881	0.6293	0.45	0.7104	0.5727	-3.8	-3.4	-1.9	-3.58	-3.18	Osteoporosis	1.102	1.09	37.4	-3.8	5.8	4.7	5.7	4.7	1	0	null	0	null	0	0	0	0	0	29.3	null	0	0	null	42.8	Sufficient	43.5	65.8	10.1	0	2.8	2	1.59	25.3	0	11.5	55.2	189.6	13.8	75.8	0	0	0	0.5303	42.3	51.9	17	73.7	46.8	10.8	1.19	5.95	0.2	-0.27	1	Risedronate	5.7	63.8	1.9	4.97	4.08	0.59	0.6	0	0	0	0	null	716	2,229	0	1.5	Low	10.6	0	12	23	0	1.21	0	43	1	30.5	0.19	0	0	15.2	5.51	0	1.2	0	null	0	null	0	1	1.6	15	0.785	50.3	43.3	29	null	0	1	0	0	6,654.31	0	0	M81.0
HC007-000002	54.6	Female	Other	Medicaid	Urban	Postmenopausal	44.6	10	171.2	171.1	0.2	76.8	26.2	Current	2	Low	4	1.0617	0.7841	0.6869	0.6397	0.5778	-2.39	-1.43	-2.48	-2.33	-1.37	Osteopenia	1.203	0.68	23.8	-2.39	3	0.7	3	0.7	0	0	null	0	null	1	0	0	1	0	6.8	null	22.3	56	Medium	11.2	Deficient	43.8	50.7	10.2	0	3.8	1.6	0.77	17.7	0	14.5	86.6	239.1	15.4	86.9	0	0	0	0.435	200	33.5	11.3	46.2	53.1	8.2	1.45	4.39	0.33	3.91	0	null	0	75.2	null	0	0	1	1	0	0	0	0	null	603	1,031	1	1	Low	7.5	0	11	27.2	0	1.23	0	48	0	10.4	0.13	1	0	19.6	6.68	0	0.4	0	null	0	null	0	0	2.2	22.9	0.856	32.7	60	21	null	0	1	0	0	7,844.24	0	0	M85.80
HC007-000003	72.5	Female	White	Private	Urban	Postmenopausal	47.9	24.6	155.1	152.6	2.5	71.6	30.7	Current	4	Low	6	1.1272	0.6634	0.496	0.5	0.45	-3.49	-3.02	-3.62	-3.22	-2.75	Osteoporosis	1.066	1.39	40.3	-3.49	5.6	2.6	5.5	2.5	0	0	null	0	null	0	0	0	0	1	35.6	null	0	0	null	41.7	Sufficient	53.8	32.8	9.2	0	4.6	1.7	3.17	19.6	0	5.9	80	101.2	19	71.6	0	0	0	0.5273	155.6	40.3	34.1	62.9	30.2	23.8	3.5	5.18	0.676	2.57	1	Denosumab	1	71.5	0	6.79	3.65	0.32	0.6	0	0	0	0	null	785	2,719	0	1.2	Low	10.5	0	2	37.3	0	0.97	0	45	0	9.5	0.14	0	0	17.3	7.42	0	0	0	null	0	null	0	0	0	0	0.866	51	44.1	25	null	0	1	0	0	4,152.49	0	0	M81.0
HC007-000004	74.4	Female	Hispanic	Private	Urban	Postmenopausal	52.6	21.8	162.7	162.5	0.2	61.2	23.2	Never	5	Low	6.5	1.1783	0.7056	0.482	0.5788	0.45	-3.1	-3.13	-2.98	-2.81	-2.84	Osteoporosis	1.335	1.4	40.4	-3.13	18.2	11.7	18.2	11.2	1	0	null	0	null	1	1	1	0	0	32.8	Malabsorption	0	0	null	7.3	Deficient	43.3	83	8.1	0	2.5	2.1	1.7	23.7	0	17.3	35.2	50	21.4	69.7	0	1	0	0.8783	69.3	8	20.7	80	37.6	14.3	4.99	5.86	0.852	-0.46	1	Risedronate	1.5	49.6	1.9	5.38	2.46	0.59	0.6	0	0	0	0	null	1,014	3,526	0	5	High	17.6	1	6	34.5	0	0.88	0	43	1	14.3	0.34	0	1	12.3	4.64	1	3.2	0	null	1	6.09	1	0	8.4	64.8	0.519	33.1	47.8	39	null	0	0	0	1	14,304.52	0	17,108.2	M80.00XA
HC007-000005	50	Female	White	Medicare	Urban	Perimenopausal	51.3	0	154.4	153.6	0.8	58.9	25	Never	1	Sedentary	6.5	1.0324	0.8014	0.5727	0.6307	0.6069	-2.23	-2.38	-2.55	-2.23	-2.38	Osteopenia	1.05	0.71	21	-2.38	3	0.3	3	0.2	0	0	null	0	null	0	1	0	0	0	8.8	Glucocorticoid	0	0	null	5	Deficient	37.1	106.9	8.9	0	3.8	1.5	4.96	12	0	117.3	12.2	248.6	8.4	107.3	0	0	0	0.2509	66	28.1	14.9	30.4	40.4	25.5	2.9	3.28	0.884	1.02	1	Denosumab	1	81	2.3	10.22	2.98	0.32	0.6	0	0	0	0	null	792	1,305	0	0.9	Low	7.7	0	18	21.9	0	1.16	0	47	0	14.9	0.16	0	0	15.3	6.48	0	5.7	0	null	0	null	0	0	3.8	19.1	0.742	50.7	42.2	21	null	1	0	0	0	6,565.55	0	0	M85.80
HC007-000006	52	Male	Other	Medicare	Suburban	null	null	null	170	167.8	2.2	89.8	31.9	Former	6	Low	3.4	0.9559	0.8038	0.7812	0.6143	0.5734	-2.21	-0.64	-2.69	-2.19	-0.62	Osteopenia	1.051	0.3	17.6	-2.21	3	0.1	3	0.1	0	0	null	0	null	0	1	0	0	0	1	Glucocorticoid	0	0	null	6.1	Deficient	43.4	63.5	9.9	0	2.8	1.6	1.69	801.1	0	23.2	6.8	246.4	16.4	74.1	0	0	0	0.3758	82.3	24.6	16	26.1	64.9	20.4	3.76	11.57	0.325	1.12	0	null	0	58.5	null	0	0	1	1	0	0	0	0	null	798	1,419	0	1	Low	7.9	0	13	42.4	0	1.04	0	50	0	20.6	0.15	0	1	28.9	10.28	0	2.5	0	null	0	null	0	0	4.1	32.4	0.876	59.2	41.8	27	null	0	1	0	0	11,096.17	0	0	M85.80
HC007-000007	66.3	Male	White	Medicare	Urban	null	null	null	168.4	168.3	0	94.9	33.5	Never	7	Moderate	1.9	1.0749	0.8096	0.668	0.732	0.4879	-2.16	-1.58	-1.72	-1.96	-1.39	Osteopenia	1.05	1.02	29	-2.16	3	0.9	3	0.8	0	0	null	0	null	0	1	0	1	1	22	Glucocorticoid	11.1	22	Medium	28.6	Insufficient	36.6	59.4	10.7	1	3.6	1.5	1.5	196.9	1	14.3	8.3	149.6	15.8	60.9	0	0	0	0.313	50.3	12.5	12.5	84.2	77.8	20.3	5.21	8.65	0.603	0.47	1	Alendronate	1	42.1	0.2	7.7	2.32	0.53	0.49	0	0	0	0	null	646	2,020	1	2.8	Low	13.8	0	15	30.2	0	1.03	0	41	1	2	0	0	0	27	9.54	0	3.5	0	null	0	null	0	0	0	0	0.804	43.8	47.5	28	null	0	0	0	0	5,915.84	0	0	M85.80
HC007-000008	61.8	Male	Black	Medicare	Urban	null	null	null	185.5	185.2	0.3	105.6	30.8	Never	2	Moderate	6.1	1.2232	0.9531	0.7208	0.9028	0.5914	-0.85	-1.14	-0.32	-0.71	-1	Osteopenia	1.322	0.87	25.4	-1.14	3	0.5	3	0.5	0	0	null	0	null	1	0	0	1	1	15.8	null	8.7	21	Low	37.2	Sufficient	16.5	69.6	9.4	0	3.6	2	1.06	369.8	0	27.6	2.9	239.9	13.1	47.1	0	0	0	0.258	59.1	13.8	30	10	89.1	8.1	5.52	4.52	1.222	0.83	0	null	0	63.8	null	0	0	1	1	0	0	0	0	null	999	1,899	1	3.1	Moderate	7	0	8	23.7	1	1.1	0	54	0	10.8	0.08	0	1	29.4	8.56	0	2.7	0	null	0	null	0	1	1.1	7.9	0.868	41.4	50.5	23	null	0	0	0	0	6,558	0	0	M85.80
HC007-000009	64.8	Female	White	Medicare	Suburban	Postmenopausal	50.9	13.9	151.1	149.8	1.3	63.3	28.2	Never	3	Sedentary	4.4	0.8	0.5449	0.6226	0.6541	0.7173	-4.56	-1.96	-2.36	-4.39	-1.78	Osteoporosis	1.098	0.48	31.4	-4.56	3	1	3	1	0	0	null	0	null	0	0	0	0	0	18.1	null	0	0	null	45.1	Sufficient	49.8	132	9	0	4	2.6	2.06	29.2	0	8.7	80.7	147.5	13.1	100	0	0	0	0.3666	57.8	19.9	41.7	48.8	76.7	19.3	2.2	5.95	0.369	0.53	1	Teriparatide	1	30.6	0.2	7.13	2.69	0.35	0.65	0	0	0	1	Denosumab	910	2,962	0	2.5	Low	7.2	0	11	21.6	0	0.88	0	56	0	30.4	0.13	1	1	13.1	5.85	0	2.3	0	null	0	null	0	0	0.9	7.6	0.798	41.4	55.4	25	null	0	0	0	0	10,762.68	0	0	M81.0
HC007-000010	56.5	Female	Hispanic	Medicare	Urban	Postmenopausal	51.9	4.6	151.8	151.6	0.2	72.8	31.6	Current	3	Moderate	9.5	1.2445	0.973	0.8422	0.7652	0.5684	-0.67	-0.13	-1.45	-0.59	-0.05	Normal	1.119	1.23	22.3	-0.67	3	0.2	3	0.2	0	0	null	0	null	0	1	0	1	0	1	Glucocorticoid	15.4	13	Medium	44	Sufficient	44.3	25.2	10.8	1	3.7	1.6	2.06	5	0	16.5	73	85.7	21.3	62.6	0	0	0	0.6665	114.4	12	11	78.2	99	29.7	1.95	7.99	0.244	1.19	0	null	0	34.8	null	0	0	1	1	0	0	0	0	null	248	2,226	1	1.2	Low	9.5	0	11	20	0	1.27	0	48	0	29.5	0.36	0	1	12.1	5.28	1	8.4	0	null	0	null	0	0	2.4	26.5	0.752	41.9	43.9	19	null	0	0	0	0	3,000	0	0	Z13.88
HC007-000011	73.8	Female	Black	Medicare	Urban	Postmenopausal	48.8	25	151.3	150.4	1	65.5	29	Never	9	Moderate	9.6	1.1127	0.6815	0.6051	0.5	0.4854	-3.32	-2.11	-3.62	-3.04	-1.82	Osteoporosis	1.05	1.68	41.3	-3.32	3	0.9	3	0.9	0	0	null	0	null	0	0	0	0	3	41.2	null	0	0	null	39.1	Sufficient	15	32.2	9.6	0	4.3	2.2	3.36	17.2	0	10.3	67.9	50	18.7	59.5	0	0	0	0.9738	115.1	15.4	30.4	117.2	66.4	7.3	5.08	6.59	0.771	0.44	0	null	0	66.9	null	0	0	1	1	0	0	0	0	null	265	1,766	0	1	Low	11.6	0	9	21.5	0	0.97	0	56	0	5.8	0	0	0	14	6.21	0	2.4	0	null	0	null	0	0	1.9	3.2	0.785	43.6	43.8	25	null	0	1	0	0	13,106.18	0	0	M81.0
HC007-000012	72.8	Female	White	Medicare	Urban	Postmenopausal	51.1	21.7	164.4	162.3	2.1	48.2	18.3	Former	7	Moderate	9.9	0.9771	0.5835	0.4809	0.6149	0.45	-4.21	-3.14	-2.68	-3.94	-2.87	Osteoporosis	1.17	0.91	39.4	-4.21	5	3.5	5	3.5	1	0	null	0	null	0	0	0	0	1	36.6	null	0	0	null	15.4	Deficient	34.5	54.9	8.7	0	4.2	1.8	2.1	46.9	0	13.8	55.5	50	26.5	90.5	0	0	0	0.4833	131.3	17.9	18.1	26.8	29.8	12.8	3.76	13.98	0.269	2.07	1	Alendronate	1.3	40.1	2.1	7.59	5.19	0.53	0.49	0	0	0	0	null	700	1,528	0	2.6	Low	9	0	11	14.2	1	1.12	0	44	1	2	0.1	0	0	14.6	5.55	0	1.3	0	null	0	null	0	0	3	27.6	0.863	56.3	57	31	null	0	0	0	0	16,682.5	0	0	M81.0
HC007-000013	65.7	Female	Asian	Private	Urban	Postmenopausal	46.2	19.5	175.4	174.4	1.1	81.8	26.9	Never	6	Low	3.4	0.9249	0.6213	0.7316	0.6554	0.6142	-3.87	-1.05	-2.35	-3.68	-0.86	Osteoporosis	1.081	1.14	34.2	-3.87	3	1	3	1	0	1	Vertebral	2	61.5	0	1	0	0	0	25.4	Glucocorticoid	0	0	null	15.2	Deficient	46.1	88.1	9.3	0	3.5	1.6	8.66	32.6	0	6.9	88.8	126.7	13.2	116.8	0	0	0	0.3088	73.3	28.5	33.2	13.3	86.1	17.9	4.03	5.39	0.747	1.06	1	Alendronate	1	64.8	0.8	9.14	6.76	0.53	0.49	0	0	0	0	null	1,091	777	0	5	Moderate	13.3	0	8	27.3	0	1.06	0	42	1	12.6	0.32	0	1	15.4	5.06	1	2.2	0	null	0	null	0	0	6.6	58.4	0.645	36	59.2	25	null	1	0	0	0	16,520.87	0	0	M81.0
HC007-000014	76.3	Female	White	Medicare	Urban	Postmenopausal	55.2	21	170.5	168.2	2.4	38	13.4	Never	3	Sedentary	6.8	1.1601	0.6445	0.45	0.5	0.5402	-3.66	-3.4	-3.62	-3.34	-3.08	Osteoporosis	1.195	1.47	41.2	-3.66	21.8	13.6	21.7	13.1	1	0	null	0	null	0	1	0	1	1	40.9	Hyperthyroidism	10.2	4	Medium	38	Sufficient	27.5	39.7	10	0	4.1	2.5	2.75	30.5	0	11.9	67.3	82.6	16.7	70.7	0	0	0	2.5	172.4	16	9.6	150	20.1	15.8	2.16	10.25	0.21	-1.94	1	Zoledronic_Acid	4.2	73.2	1.2	7.75	8.63	0.3	0.59	0	0	0	0	null	1,149	3,095	1	3.1	Moderate	14.9	0	14	29	0	1.33	0	50	0	2	0.08	1	0	12.1	4.29	1	4.1	0	null	0	null	0	0	2.5	20	0.832	38.6	47.4	23	null	0	0	0	0	5,634.85	0	0	M81.0
HC007-000015	69.7	Female	Hispanic	Medicare	Suburban	Postmenopausal	49	20.7	147.7	147.3	0.4	61.8	28.5	Current	9	High	7.4	0.9245	0.5916	0.6012	0.6335	0.5645	-4.14	-2.14	-2.53	-3.9	-1.9	Osteoporosis	1.05	1.78	37.1	-4.14	5.7	2.8	5.6	2.8	0	0	null	0	null	0	0	0	1	1	28.1	null	21.2	44	Medium	46.9	Sufficient	34	52.6	9.4	0	3.4	2.6	1	17	0	19.9	36.1	85.7	17.5	66.2	0	0	0	1.1398	62.8	18	21.9	150	120	30.8	4.13	3.29	1.254	-1.28	1	Alendronate	2.9	47.8	3	8.06	2.88	0.53	0.49	0	0	0	0	null	1,028	2,502	1	3.4	Moderate	6.4	0	12	19.1	1	1.15	0	39	1	10.8	0.08	0	1	13.4	6.18	0	2.9	0	null	0	null	0	0	1.5	16.5	0.881	42.8	51.3	26	null	0	1	0	0	9,302.74	0	0	M81.0
HC007-000016	56.4	Female	White	Private	Rural	Postmenopausal	57.1	0	170.9	169.4	1.5	59.3	20.7	Never	5	Low	7.2	0.935	0.7825	0.7823	0.8139	0.7591	-2.4	-0.63	-1.05	-2.33	-0.55	Osteopenia	1.155	0.5	15.8	-2.4	3	0.2	3	0.2	0	1	Wrist	0	49.1	0	0	0	0	1	20.4	null	0	0	null	12.6	Deficient	61.3	67.8	9.9	0	3.4	2.1	0.94	28.4	0	11.1	40.8	134	20.5	71.9	0	0	0	0.9266	163.3	34.9	17	103.4	24.6	21.6	1.74	3.53	0.492	1.77	0	null	0	70.5	null	0	0	1	1	0	0	0	0	null	754	1,927	0	1.9	Low	12	0	11	20.3	0	1.18	0	55	0	14.9	0.35	0	0	15.5	5.39	1	4.6	0	null	0	null	0	0	0.9	9.9	0.805	38.7	59.7	20	null	0	0	0	0	6,400.13	0	0	M85.80
HC007-000017	68.7	Female	White	Private	Urban	Postmenopausal	50.9	17.8	167.6	165.3	2.3	70.1	25.6	Never	4	Low	4.7	0.9627	0.6318	0.5209	0.5485	0.4949	-3.77	-2.81	-3.23	-3.55	-2.59	Osteoporosis	1.079	0.31	35.3	-3.77	3.8	1.8	3.7	1.8	0	0	null	0	null	0	0	0	0	2	36.3	null	0	0	null	45.1	Sufficient	22.4	45	8.4	0	3	2.1	2.91	24.8	0	8.7	32.1	173.4	22.8	59.8	0	0	0	1.2722	52.8	9.9	26	150	62.3	18.4	3.39	12.8	0.265	-1.86	1	Risedronate	2	61.8	5.6	3.96	4.87	0.59	0.6	0	0	0	0	null	1,239	2,086	0	2.3	Low	9.7	0	11	15.2	1	1.11	0	48	0	8.3	0.23	1	0	17.4	6.37	0	2.5	0	null	0	null	0	0	2.7	0	0.847	30.9	60	24	null	1	1	0	0	3,805.14	0	0	M81.0
HC007-000018	55.4	Female	White	Private	Suburban	Postmenopausal	54.1	1.3	150.2	149.8	0.4	75.9	33.8	Never	5	Moderate	8.3	1.0595	0.9345	0.8426	0.8739	0.615	-1.02	-0.13	-0.56	-0.96	-0.06	Osteopenia	1.097	1.41	17.1	-1.02	3	0.1	3	0.1	0	0	null	0	null	0	1	0	0	0	1	Glucocorticoid	0	0	null	5	Deficient	48.7	67.5	8.5	0	4.3	2	0.98	15.4	0	6.8	89	109.1	16.5	64.2	0	0	0	0.717	36.3	24.4	20.5	57	82.4	22.6	3.17	4.94	0.642	-0.89	0	null	0	59.3	null	0	0	1	1	0	0	0	0	null	583	1,913	0	1.8	Low	12.1	0	11	26	0	1.56	0	47	0	18.6	0.22	0	0	14.6	6.49	0	2.8	0	null	0	null	0	0	1.6	3.8	0.859	41.7	50.9	26	null	0	0	0	0	8,362.87	0	0	M85.80
HC007-000019	73.8	Male	White	Medicare	Suburban	null	null	null	176.8	174.5	2.3	96.2	31.6	Former	4	Sedentary	5.5	1.093	0.7025	0.5757	0.756	0.6393	-3.13	-2.35	-1.52	-2.85	-2.07	Osteoporosis	1.06	0.67	35	-3.13	3.8	3.8	3.6	3.8	1	1	Vertebral	3	66.1	0	0	0	0	1	44.6	null	0	0	null	32.5	Sufficient	37	75.3	9	0	3.4	2	3.03	405.2	0	28.2	14.9	71.4	10.5	59	0	0	0	0.3661	129.5	26.2	20.2	43.2	50.3	22	3.18	3.55	0.897	2.32	1	Teriparatide	10	64.2	5.3	13.15	9.12	0.35	0.65	0	0	0	1	Alendronate	697	587	0	6.9	High	21.5	1	5	24.6	1	1	0	41	1	17.5	0.31	0	1	22.9	7.51	0	2.6	0	null	0	null	0	0	7.1	77.9	0.668	48.4	53.3	43	null	0	1	0	0	3,861.78	0	0	M81.0
HC007-000020	64.5	Male	White	Private	Urban	null	null	null	176.9	176.8	0.1	66.2	21.2	Never	9	Moderate	5.8	1.107	0.8136	0.5996	0.8034	0.6185	-2.12	-2.15	-1.14	-1.95	-1.98	Osteopenia	1.05	0.37	27.6	-2.15	3	0.9	3	0.9	0	0	null	0	null	0	1	0	0	2	29	Glucocorticoid	0	0	null	25.5	Insufficient	32.7	27.7	9.2	0	2.5	2.1	3.74	525.4	0	18.5	6.4	99.4	12.4	92	0	0	0	0.6673	70	26.5	19.2	123.2	14.3	15.3	4.43	5.87	0.755	0.08	0	null	0	72.2	null	0	0	1	1	0	0	0	0	null	373	863	0	2.5	Low	9.3	0	8	31.5	0	1.09	0	41	1	3.3	0.16	0	0	23.4	7.47	0	3.8	0	null	0	null	0	0	4	38.6	0.722	44.3	48.9	23	null	1	1	0	0	10,795.94	0	0	M85.80
HC007-000021	63.2	Female	Hispanic	Medicare	Suburban	Postmenopausal	49.2	13.9	164.9	163.8	1	76.2	28.4	Never	4	Sedentary	2.1	1.1619	0.8047	0.4599	0.5912	0.45	-2.2	-3.32	-2.88	-2.04	-3.16	Osteoporosis	1.161	1.71	30.5	-3.32	12.2	12.2	11.9	11.9	1	1	Vertebral	1	60.8	1	1	0	0	1	42	Malabsorption	0	0	null	24.1	Insufficient	42.1	41.8	9.6	0	3.9	2.2	3.81	7.1	0	5	62.1	185.5	16.7	70.1	0	0	0	1.2507	82.1	17.6	37.4	106.9	24.9	12.6	1.8	10.6	0.17	-1.07	1	Denosumab	2.1	80.7	0.4	4.53	10.1	0.32	0.6	0	0	0	0	null	696	1,836	0	0.9	Low	7.8	0	11	39.7	0	1.08	0	56	0	27.9	0.15	0	0	14.5	5.39	1	5.4	0	null	0	null	0	0	4.9	33.5	0.743	34.7	37.6	19	null	1	0	0	0	12,047.2	0	0	M81.0
HC007-000022	58.2	Male	Hispanic	Medicare	Suburban	null	null	null	169.7	169.5	0.2	73.5	25.6	Never	7	Moderate	6.9	1.1697	0.9324	0.6743	0.7484	0.6395	-1.04	-1.53	-1.59	-0.94	-1.43	Osteopenia	1.234	0.79	22.6	-1.53	3	0.3	3	0.3	0	0	null	0	null	1	0	1	0	1	15.2	null	0	0	null	27.4	Insufficient	56.5	24.5	9.8	0	3.4	2.5	1.09	501.8	0	13.8	13.8	133.5	21.6	101.9	0	0	0	0.5142	44.2	13.6	18.6	93	47.8	24.6	4.21	4.26	0.989	-0.18	0	null	0	68.8	null	0	0	1	1	0	0	0	0	null	541	1,823	0	3.3	Moderate	14.4	0	11	40.1	0	0.65	1	48	0	32.4	0.24	0	0	27.4	9.52	0	5.6	0	null	0	null	0	0	4.9	43	0.757	39.7	50.4	29	null	1	1	0	0	15,257.32	0	0	M85.80
HC007-000023	77.2	Male	Hispanic	Medicare	Rural	null	null	null	177.4	175.9	1.5	82.3	26.6	Never	4	High	4.9	1.0028	0.6605	0.5806	0.6718	0.4704	-3.51	-2.31	-2.22	-3.19	-1.99	Osteoporosis	1.158	0.48	37.8	-3.51	3	2.3	3	2.2	0	0	null	0	null	1	0	0	0	1	35.1	null	0	0	null	15	Deficient	43.7	70.4	10.9	1	3.5	1.8	3.81	293.6	1	27.1	10	126	8.8	62.1	0	0	0	0.5455	35.5	43.6	28.3	24.1	55	10.3	3.03	5.89	0.515	-0.47	0	null	0	52	null	0	0	1	1	0	0	0	0	null	1,261	1,990	0	0.1	Low	10.9	0	12	44.8	0	1.01	0	46	0	35.8	0.1	0	0	23.1	7.47	0	6.8	0	null	0	null	0	0	0	7.1	0.832	60	57.6	19	null	0	0	0	0	10,336.25	0	0	M81.0
HC007-000024	63.5	Female	White	Medicare	Rural	Postmenopausal	48.6	14.8	146	145.1	0.9	94.6	44.9	Never	3	High	6.5	0.9732	0.7621	0.7938	0.6424	0.6136	-2.59	-0.54	-2.46	-2.43	-0.37	Osteoporosis	1.163	0.94	31	-2.59	3	0.3	3	0.3	0	0	null	0	null	0	1	0	0	1	13.5	Malabsorption	0	0	null	33.2	Sufficient	58.9	40.8	9	0	3.5	2	2.51	14.8	0	9.5	45.2	222.9	10.1	63.9	0	0	0	0.3901	46.4	15	25.7	28.7	36.6	14.5	2.02	2.6	0.775	0.18	1	Zoledronic_Acid	9.2	72.1	2.2	9.3	4.79	0.3	0.59	0	0	0	0	null	1,202	3,358	0	2.8	Low	16.8	1	13	27.8	0	1.28	0	48	0	19.8	0.4	0	1	13.2	6.26	0	1.4	0	null	0	null	0	0	2	31.3	0.839	43.2	42.7	19	null	0	1	0	0	6,505.26	0	0	M81.0
HC007-000025	60.7	Female	White	Medicare	Urban	Postmenopausal	50.6	10.1	159.4	158.1	1.3	47.9	19.1	Former	2	High	6	0.8467	0.6203	0.647	0.754	0.6031	-3.88	-1.76	-1.54	-3.75	-1.63	Osteoporosis	1.05	0.7	27.5	-3.88	3	0.4	3	0.4	0	0	null	0	null	0	1	0	0	1	18.6	Hyperparathyroidism	0	0	null	27.8	Insufficient	34.9	76.8	9.2	0	3.4	2	1.31	21.4	0	13.6	64.1	304.5	19.8	100.1	0	0	0	0.5536	69.2	13.3	28.5	72.7	41.5	8.4	1.55	4.86	0.319	0.35	1	Risedronate	3.8	51.8	3.7	5.3	3.8	0.59	0.6	0	0	0	0	null	818	1,770	0	0.9	Low	8.3	0	10	26.5	0	1.18	0	47	0	35.3	0.04	0	1	15.7	6.29	0	1.9	0	null	0	null	0	0	0.3	0	0.805	39.2	35	17	null	0	0	0	0	7,278.87	0	0	M81.0
HC007-000026	61.5	Female	White	Medicare	Urban	Postmenopausal	49.2	12.3	169	166.9	2	73.9	26.5	Never	3	Moderate	5.9	0.9732	0.7198	0.769	0.6489	0.45	-2.97	-0.74	-2.4	-2.84	-0.6	Osteoporosis	1.236	0.92	28.8	-2.97	3	0.2	3	0.2	0	0	null	0	null	1	0	0	0	0	8.1	null	0	0	null	40.1	Sufficient	54.4	44.9	9	0	5	2.3	1.79	5.7	0	5	92.7	171.2	9.5	72.5	0	0	0	1.3813	60.8	22.2	13.3	150	19.2	21.6	7.71	9.4	0.821	-1.93	0	null	0	70.9	null	0	0	1	1	0	0	0	0	null	940	1,389	0	2.5	Low	7.9	0	9	18.1	1	1.4	0	51	0	29	0.28	0	0	17	6.11	0	2.2	0	null	0	null	1	0	0.6	0	0.792	44.5	52.1	24	null	0	0	0	0	8,506.61	0	0	M81.0
HC007-000027	70.3	Female	Black	Private	Urban	Postmenopausal	57.9	12.4	161.1	160.3	0.8	73.5	28.6	Never	5	Sedentary	5.4	0.9583	0.6288	0.6346	0.6542	0.5491	-3.8	-1.86	-2.36	-3.56	-1.62	Osteoporosis	1.137	0.91	34.1	-3.8	5.9	2.9	5.6	2.9	0	0	null	0	null	1	1	0	0	1	26.9	GnRH_Agonist	0	0	null	49.3	Sufficient	40.1	36	10	0	4.4	2.7	2.78	34.6	0	9.3	92.7	152	10.4	66	0	0	0	0.9133	27.1	15.8	26.5	92	97.1	27.8	2.9	4.22	0.687	-1.6	1	Denosumab	5.2	80.3	1.8	9.96	7.83	0.32	0.6	0	0	0	0	null	618	2,042	0	3.7	Moderate	23.4	1	13	16.7	1	1.2	0	50	0	15.1	0.26	0	0	13.5	5.24	1	4	0	null	0	null	0	0	1	3.2	0.83	47.3	35.7	32	null	1	1	0	0	16,624.41	0	0	M81.0
HC007-000028	68.7	Male	Asian	Medicare	Urban	null	null	null	177.6	177.3	0.3	70.7	22.5	Former	3	High	7.2	1.0329	0.7283	0.7382	0.7698	0.5659	-2.9	-1	-1.41	-2.67	-0.77	Osteoporosis	1.223	0.78	31	-2.9	3	0.7	3	0.7	0	0	null	0	null	0	1	0	1	2	25.5	Glucocorticoid	18.9	3	Medium	28.8	Insufficient	37.4	39.8	10.1	0	3.9	2.3	1.25	532.3	0	10	4.7	50.9	21.7	70.5	0	0	0	0.2321	111.4	35.3	22.9	13.8	33.1	9.4	2.51	3.39	0.742	2.21	1	Denosumab	7.1	68.8	0.8	5.39	6.84	0.32	0.6	0	0	0	0	null	39	882	1	1.6	Low	12.8	0	11	33.5	0	1.14	0	47	0	2	0.09	0	0	26.8	8.52	0	1.8	0	null	0	null	0	0	3.4	21.4	0.794	42.4	37	29	null	0	0	0	0	16,712.24	0	0	M81.0
HC007-000029	69.1	Female	White	Medicare	Urban	Postmenopausal	55.6	13.5	167.2	164.9	2.3	61.1	22.5	Former	9	High	5.1	0.9415	0.6372	0.6745	0.6055	0.5573	-3.73	-1.53	-2.76	-3.5	-1.3	Osteoporosis	1.196	0.64	33.9	-3.73	3	0.9	3	0.9	0	0	null	0	null	0	1	0	0	1	24	Multiple_Myeloma	0	0	null	15.5	Deficient	45.1	126.5	9.1	0	3.7	2.2	2.47	37.3	0	12.8	25	143.5	14.9	101.8	0	0	1	0.4857	53.8	19.5	12.4	124.4	59.3	13.9	1.69	4.23	0.4	0.13	0	null	0	43.8	null	0	0	1	1	0	0	0	0	null	571	2,124	0	2.8	Low	18.7	1	9	23.8	0	1.23	0	45	0	24.2	0.25	0	0	14.2	5.23	1	2.6	0	null	0	null	0	0	1.4	5.1	0.888	51.6	36.6	21	null	1	0	0	0	7,670.54	0	0	M81.0
HC007-000030	69.3	Female	Hispanic	Medicare	Rural	Postmenopausal	50.4	18.9	167.8	164.5	3.3	79.6	29.4	Never	7	Low	2.3	0.9963	0.6551	0.6592	0.7581	0.5561	-3.56	-1.66	-1.51	-3.33	-1.43	Osteoporosis	1.05	0.3	36.1	-3.56	3	1.5	3	1.4	0	0	null	0	null	1	1	0	0	0	19.9	Malabsorption	0	0	null	11.1	Deficient	39.1	40.5	10.6	1	4.2	2.3	5.5	38.6	0	14	41.7	124.8	14.5	76.2	0	0	0	1.2184	113.5	37.4	18.4	114.4	80.7	11.8	5.17	4.56	1.134	-0.21	1	Raloxifene	2.6	57.4	4.8	2.13	1.96	0.64	1	0	0	0	0	null	1,024	1,420	0	4.5	Moderate	11.4	0	7	17.3	1	1.11	0	38	1	16.2	0.19	1	0	14.3	5.3	1	5.4	0	null	0	null	0	0	0.3	4.2	0.867	45.2	34	27	null	0	0	0	0	13,077.38	0	0	M81.0
HC007-000031	86.4	Female	White	Medicare	Urban	Postmenopausal	51.8	34.6	170.2	167.8	2.4	46.2	16.4	Never	4	Low	6.8	1.1152	0.5171	0.4716	0.5	0.4915	-4.82	-3.22	-3.62	-4.38	-2.78	Osteoporosis	1.05	0.36	52.7	-4.82	34.2	35	33.8	34.3	1	1	Vertebral	2	85.9	1	0	0	0	3	69.9	null	0	0	null	50.8	Sufficient	39.3	32.9	9	0	3.7	2.4	3.93	32.5	0	6.2	88.8	148.9	22.8	86.6	0	0	0	0.7266	47.3	26.9	50	101.3	22.5	25.7	4.97	8.46	0.588	-0.63	0	null	0	74.9	null	0	0	1	1	0	0	0	0	null	931	2,180	0	4.6	Moderate	13.6	0	7	25.4	0	0.88	0	36	1	26.2	0.01	0	1	12.5	4.44	1	6.1	0	null	0	null	0	0	2.7	17.7	0.831	26.8	55.4	35	null	1	0	0	0	6,180.67	0	0	M81.0
HC007-000032	60.9	Female	White	Medicare	Urban	Postmenopausal	47	13.9	167.1	166.9	0.2	67.1	24.1	Never	8	Sedentary	3.7	1.2357	0.8608	0.45	0.7104	0.5926	-1.69	-3.4	-1.9	-1.56	-3.27	Osteoporosis	1.21	0.59	29.1	-3.4	4.7	3.3	4.6	3.1	1	0	null	0	null	0	1	0	0	1	28.6	Hypogonadism	0	0	null	49	Sufficient	43.9	45.8	10	0	4	2.7	2.12	28.2	0	13.7	69.6	110.1	10.7	66.8	0	0	0	0.6614	69.7	18.5	17.1	56	42.6	30.5	4.52	7.12	0.635	0.09	1	Teriparatide	5	70.2	0.1	15.35	7.4	0.35	0.65	0	0	0	0	null	682	1,855	0	1.6	Low	5	0	13	25.9	0	1.04	0	46	0	26.4	0.11	0	1	15.4	5.52	0	5.4	1	20	0	null	0	0	0.2	1.2	0.678	35.5	43	29	19.7	0	1	1	1	13,091.77	31,417.71	0	M80.052A
HC007-000033	59.9	Male	White	Medicare	Suburban	null	null	null	170	168.1	1.9	78.7	27.8	Current	6	Low	2.6	1.0632	0.7885	0.8674	0.7448	0.5976	-2.35	0.08	-1.62	-2.23	0.2	Osteopenia	1.05	1.16	23.9	-2.35	3	0.1	3	0.1	0	0	null	0	null	0	0	0	0	0	1.9	null	0	0	null	39.4	Sufficient	25.5	32.7	10.3	0	3.9	1.5	2.36	450.2	0	13.6	2	147.2	9.7	96	0	0	0	0.4718	80.5	36.3	17.3	50.7	46	11.8	2.91	7.76	0.375	0.83	0	null	0	59.4	null	0	0	1	1	0	0	0	0	null	1,021	1,886	0	3.8	Moderate	12.9	0	17	45.9	0	0.55	1	49	0	30.7	0	0	1	29.4	10.4	0	4.6	0	null	0	null	0	0	4.5	54.8	0.743	40.7	60	31	null	0	0	0	0	6,717.52	0	0	M85.80
HC007-000034	56.9	Female	White	Medicare	Urban	Postmenopausal	51.6	5.2	166.1	164.9	1.2	58.5	21.5	Never	9	Moderate	3.3	0.9053	0.7089	0.8215	0.812	0.6879	-3.07	-0.3	-1.07	-2.99	-0.22	Osteoporosis	1.05	1.07	23.2	-3.07	3	0.1	3	0.1	0	0	null	0	null	0	0	0	0	1	6.8	null	0	0	null	27.8	Insufficient	33.6	57.5	8.6	0	3.7	2.2	1.37	14	0	16.3	56.5	176	24.1	77.2	0	0	0	0.6345	94.6	16.4	24	47.9	35.2	3.2	4.37	6.08	0.719	0.78	1	Zoledronic_Acid	1	35.7	2.6	6.25	6.21	0.3	0.59	0	0	0	0	null	658	2,501	0	2.3	Low	10.7	0	11	22.7	0	1.44	0	36	1	12.6	0.18	1	0	11.2	4.11	1	2.7	0	null	0	null	0	0	0.1	0	0.817	46.9	53.1	24	null	0	0	0	0	9,037.74	0	0	M81.0
HC007-000035	71.2	Female	Hispanic	Private	Urban	Postmenopausal	55.8	15.4	162.9	162.2	0.7	74	28.1	Never	3	Low	6.1	0.9599	0.6312	0.4921	0.5283	0.668	-3.78	-3.05	-3.39	-3.53	-2.79	Osteoporosis	1.05	0.57	35.9	-3.78	21.8	19.7	21.5	19.5	1	1	Wrist	0	67.9	0	1	0	1	0	41.8	Hyperparathyroidism	5	13	Low	38.4	Sufficient	45.8	43.7	9.7	0	4.1	1.5	1.4	33.3	0	5	50	232.1	17.2	87.7	0	0	0	0.4802	57.6	19	16.1	148.5	63.6	26.7	1.99	4.54	0.438	0.24	1	Alendronate	2.5	57.9	1.7	4.38	6.16	0.53	0.49	0	0	0	0	null	457	2,587	1	2.8	Low	11.1	0	8	26.1	0	0.98	0	51	0	15.3	0.17	1	1	18	6.85	0	4	0	null	0	null	0	0	1.6	15.9	0.828	37.6	60	26	null	0	0	0	0	5,304.19	0	0	M81.0
HC007-000036	76.3	Female	Asian	Medicaid	Rural	Postmenopausal	51.7	24.6	161.6	161.5	0.2	83.1	31.9	Never	4	Low	5.3	1.1312	0.6718	0.6137	0.5	0.5325	-3.41	-2.04	-3.62	-3.1	-1.72	Osteoporosis	1.053	0.52	42.6	-3.41	10.2	6.3	10	6.1	1	1	Wrist	0	66.6	1	0	0	0	1	44.8	null	0	0	null	45.3	Sufficient	47.9	51.1	8	0	3.4	2.3	0.68	32.6	0	10.3	40.9	204.4	19.4	86.5	0	0	0	0.4145	81.7	27.9	21.2	75.2	28.7	15.3	3.34	4.23	0.791	1.01	0	null	0	56.5	null	0	0	1	1	0	0	0	0	null	1,021	3,626	0	5.4	High	16.7	1	17	19.3	1	0.76	1	47	0	2	0.35	0	1	15	5.74	0	6.3	0	null	0	null	0	0	4.9	27.7	0.76	49.6	43.5	31	null	0	0	0	0	3,932.37	0	0	M81.0
HC007-000037	63.9	Female	White	Medicare	Urban	Postmenopausal	55.2	8.7	159.3	157.9	1.4	63.2	25.3	Never	5	Low	1	1.0245	0.7386	0.7061	0.6261	0.5796	-2.8	-1.27	-2.59	-2.64	-1.1	Osteoporosis	1.055	0.63	28.8	-2.8	3	2.8	3	2.7	0	1	Vertebral	5	52.9	0	1	0	1	2	35.2	CKD	12.3	51	Medium	18.3	Deficient	27.9	67.7	9.9	0	3.6	2.2	2.38	19.4	0	12.6	106.4	205.1	14.4	51.3	0	0	0	0.9745	88.1	24.4	16.7	150	41.1	15.4	2.92	7.29	0.401	-0.23	1	Raloxifene	5.5	58.2	0.3	1.15	3.27	0.64	1	0	0	0	0	null	616	2,555	1	1.3	Low	9.6	0	10	25.4	0	0.97	0	43	1	22.7	0.04	0	0	14.1	5.65	0	5.3	0	null	0	null	0	0	4.7	46.6	0.762	31.5	50.5	28	null	1	0	0	0	4,290.1	0	0	M81.0
HC007-000038	56.6	Female	White	Private	Urban	Postmenopausal	52.9	3.7	152.5	151.2	1.3	78.9	34.5	Never	3	Sedentary	4.7	0.9673	0.7786	0.6372	0.7826	0.6473	-2.44	-1.84	-1.31	-2.36	-1.76	Osteopenia	1.05	3.52	21.1	-2.44	3	0.2	3	0.2	0	0	null	0	null	0	0	0	0	0	10.8	null	0	0	null	27.4	Insufficient	42.2	42.7	8.7	0	3.1	1.8	3.22	31.3	0	20.1	99.4	183.7	15.5	73.6	0	0	0	0.9714	60.8	16.2	23.5	65.5	33.2	24.3	3.43	12.27	0.28	-0.91	0	null	0	57.6	null	0	0	1	1	0	0	0	0	null	1,107	1,804	0	3	Moderate	7.2	0	9	25.2	0	1.48	0	43	1	34.3	0	0	0	19.3	8.45	0	5.8	0	null	0	null	0	0	2.6	32.3	0.787	35.2	39.1	19	null	1	0	0	0	10,707.88	0	0	M85.80
HC007-000039	56.8	Female	Black	Medicaid	Urban	Postmenopausal	55.9	0.9	154.3	154	0.3	68.7	29	Never	6	High	8.1	1.1258	0.9868	0.5679	0.861	0.6585	-0.55	-2.42	-0.66	-0.47	-2.34	Osteopenia	1.193	3.13	17.3	-2.42	3	0.7	3	0.7	0	0	null	0	null	0	0	0	0	2	24.5	null	0	0	null	11.5	Deficient	43.2	43.6	9.7	0	3.2	1.5	1.9	16.7	0	12.5	48.6	113.9	12.5	93.1	0	0	0	1.0962	39.4	11	19.5	44	120	12.5	1.21	3.93	0.308	-1.76	1	Alendronate	1	45.6	2.2	9.84	4.23	0.53	0.49	0	0	0	0	null	200	1,493	0	2.1	Low	10.6	0	11	28.1	0	1.11	0	44	1	36.3	0	0	1	24.3	10.26	0	5.9	0	null	0	null	0	0	1.8	6	0.811	40.9	46.1	23	null	0	1	0	0	4,582.81	0	0	M85.80
HC007-000040	71.5	Female	Other	Uninsured	Rural	Postmenopausal	50.8	20.7	159	158.4	0.6	55.5	22.1	Former	7	Sedentary	4.5	1.1522	0.6816	0.4923	0.5	0.5064	-3.32	-3.05	-3.62	-3.06	-2.79	Osteoporosis	1.058	0.76	38.2	-3.32	8	5.5	7.8	5.4	1	0	null	0	null	0	0	0	1	1	35	null	21.3	50	Medium	25.2	Insufficient	47.7	49.1	9.9	0	2.5	2	1.08	17.4	0	13.1	29.9	161.3	17.6	92.7	0	0	0	0.7989	49.1	21.8	43.7	69	28.7	10.9	7.64	3.79	2.013	-0.77	1	Risedronate	1	62.3	0.8	5.03	2.09	0.59	0.6	0	0	0	0	null	629	2,277	1	3.6	Moderate	10.9	0	9	24.3	0	1.07	0	35	1	8	0.49	0	0	10.6	4.24	1	3.3	0	null	0	null	0	0	2	9	0.893	50	58	33	null	1	1	0	0	6,745.35	0	0	M81.0
HC007-000041	72.4	Female	Hispanic	Medicare	Urban	Postmenopausal	58.2	14.3	162.7	162.5	0.2	64.4	24.4	Former	3	Sedentary	5.1	1.0449	0.6413	0.7252	0.5246	0.6606	-3.69	-1.11	-3.42	-3.42	-0.84	Osteoporosis	1.171	1.28	36.2	-3.69	3	0.6	3	0.6	0	1	Wrist	0	66.3	0	0	0	0	1	36.1	null	0	0	null	48.6	Sufficient	28.6	18.6	10.1	0	3.8	2.1	2.09	34.3	0	14.3	68.4	70.1	20.2	95.1	0	0	0	1.2404	54.8	15.9	20.4	150	58.1	12.6	6.74	3.6	1.872	-1.73	1	Romosozumab	6.2	52	0.8	13.35	10.05	0.27	0.62	0	0	0	0	null	979	3,169	0	6.3	High	14.4	0	14	9.8	1	1.47	0	43	1	2	0.65	0	1	14.7	5.55	0	5.3	0	null	0	null	0	0	0.8	12.8	0.848	52.1	47.7	34	null	0	0	0	0	12,486.41	0	0	M81.0
HC007-000042	70.4	Male	White	Medicaid	Urban	null	null	null	179.8	176.6	3.2	52	16.7	Former	6	Sedentary	7.8	1.0629	0.6712	0.6439	0.6121	0.4909	-3.42	-1.78	-2.7	-3.17	-1.54	Osteoporosis	1.265	1.31	32.3	-3.42	3	1.7	3	1.7	0	0	null	0	null	1	0	0	0	0	21.5	null	0	0	null	42.1	Sufficient	35.9	32.2	9.9	0	4	2	5.12	681.7	0	33	11.1	107	17	71.1	0	0	0	0.5327	52.6	22.3	18.3	45.3	98.2	19.2	1.69	8.72	0.194	-0.02	1	Alendronate	2.5	58.9	1.4	6.81	6.46	0.53	0.49	0	0	0	0	null	948	2,685	0	3.6	Moderate	10.6	0	6	43.6	0	1.21	0	44	1	6.3	0.48	0	0	27.8	8.92	0	3.2	0	null	0	null	0	0	2.7	18.7	0.826	44.8	46.4	28	null	1	1	0	0	14,007.83	0	0	M81.0
HC007-000043	58.3	Female	Hispanic	Medicaid	Urban	Postmenopausal	48.7	9.6	160.7	159.9	0.8	58.2	22.8	Former	3	Moderate	7.3	1.0767	0.8011	0.5874	0.6965	0.6695	-2.24	-2.25	-2.01	-2.14	-2.16	Osteopenia	1.156	0.86	25.8	-2.25	3	0.5	3	0.5	0	0	null	0	null	0	0	0	0	1	19.6	null	0	0	null	28.9	Insufficient	39.4	57.5	9.4	0	4.1	1.8	3.75	22.2	0	9.7	77.6	244.3	21.3	105.9	0	0	0	0.9162	133.1	18.2	30.2	150	25.3	23.3	4	5.89	0.68	1.04	0	null	0	60.3	null	0	0	1	1	0	0	0	0	null	733	1,430	0	0.8	Low	8.3	0	13	23.3	0	1.02	0	56	0	17.9	0	0	1	11.6	4.54	1	5.2	0	null	0	null	0	0	4	46.1	0.794	44.4	47.8	26	null	0	0	0	0	4,902.46	0	0	M85.80
HC007-000044	67.3	Female	White	Private	Urban	Postmenopausal	47.4	20	168	166.9	1.1	74	26.6	Never	3	Moderate	7.7	1.0213	0.6848	0.5241	0.8091	0.5147	-3.29	-2.78	-1.09	-3.09	-2.57	Osteoporosis	1.05	0.78	35.4	-3.29	4.8	2.4	4.6	2.3	0	0	null	0	null	0	0	0	1	0	25	null	12.7	34	Medium	5	Deficient	26.6	101.6	9.2	0	3	1.7	1.96	20.8	0	5	82.1	156.3	19.3	56.2	0	0	0	0.676	97.8	15.9	11.5	40.5	42	33.9	1.43	7.7	0.185	0.75	1	Zoledronic_Acid	9.3	77.1	1.9	5.73	8.8	0.3	0.59	0	0	0	0	null	886	2,362	1	1.5	Low	9.8	0	11	24.5	0	0.66	1	51	0	19.3	0	0	0	11	3.95	1	6.5	0	null	0	null	0	0	0	0	0.841	37.2	49	25	null	1	1	0	0	3,000	0	0	M81.0
HC007-000045	66.2	Female	Other	Medicare	Rural	Postmenopausal	58	8.2	168.6	167.5	1	71.3	25.4	Current	4	Sedentary	1	1.0205	0.6679	0.694	0.5494	0.4525	-3.45	-1.37	-3.22	-3.25	-1.17	Osteoporosis	1.127	1.32	30	-3.45	4.5	2.3	4.3	2.2	0	0	null	0	null	1	1	0	1	1	20.7	Hypogonadism	6.3	19	Low	17.8	Deficient	15	165.7	9.4	0	3.8	2	8.38	27.1	0	5	41.6	139.3	10.8	38.4	1	0	0	0.4745	45	19.5	39.3	31.3	24.4	18.4	3.13	4.77	0.655	-0.06	0	null	0	75.7	null	0	0	1	1	0	0	0	0	null	842	2,177	1	2.5	Low	8.8	0	9	26.8	0	1.18	0	56	0	2	0	0	1	18	6.43	0	7.1	0	null	0	null	0	0	0.6	15.7	0.865	33.9	49	30	null	1	0	0	0	5,352.99	0	0	M81.0
HC007-000046	67.2	Male	White	Medicare	Urban	null	null	null	169.8	167.9	1.9	66.9	23.7	Former	6	Sedentary	9.3	1.2643	0.8577	0.5036	0.5923	0.5454	-1.72	-2.95	-2.87	-1.51	-2.75	Osteoporosis	1.132	0.46	29.8	-2.95	4	2.2	3.9	2.1	0	0	null	0	null	0	1	0	0	1	31	Glucocorticoid	0	0	null	28.4	Insufficient	29.9	36.3	8.7	0	3.6	1.8	10	205.7	1	19.8	9.1	145.5	15.3	64.6	0	0	0	0.3319	118.8	21.3	13.5	31.9	14.6	14	1	7.92	0.126	2.14	1	Alendronate	9.2	55	5.3	8.7	4.46	0.53	0.49	1	5	1	0	null	353	2,839	0	1	Low	9.8	0	10	37.4	0	0.89	0	48	0	13.1	0.28	0	0	25.3	8.97	0	5.2	0	null	0	null	0	0	1.2	31.7	0.828	41	57.3	28	null	1	0	0	0	8,843.72	0	0	M81.0

End of preview. Expand in Data Studio

YAML Metadata Warning:The task_categories "survival-analysis" is not in the official list: text-classification, token-classification, table-question-answering, question-answering, zero-shot-classification, translation, summarization, feature-extraction, text-generation, fill-mask, sentence-similarity, text-to-speech, text-to-audio, automatic-speech-recognition, audio-to-audio, audio-classification, audio-text-to-text, voice-activity-detection, depth-estimation, image-classification, object-detection, image-segmentation, text-to-image, image-to-text, image-to-image, image-to-video, unconditional-image-generation, video-classification, reinforcement-learning, robotics, tabular-classification, tabular-regression, tabular-to-text, table-to-text, multiple-choice, text-ranking, text-retrieval, time-series-forecasting, text-to-video, image-text-to-text, image-text-to-image, image-text-to-video, visual-question-answering, document-question-answering, zero-shot-image-classification, graph-ml, mask-generation, zero-shot-object-detection, text-to-3d, image-to-3d, image-feature-extraction, video-text-to-text, keypoint-detection, visual-document-retrieval, any-to-any, video-to-video, other

HC-END-007 — Osteoporosis & Metabolic Bone Disease Synthetic Dataset (Sample)

XpertSystems.ai · Synthetic Data Factory · Endocrinology Vertical

A deeply trial-calibrated synthetic cohort of osteoporosis and metabolic bone disease patients spanning DXA bone mineral density (lumbar/femoral neck/total hip), WHO classification, FRAX & Garvan fracture risk, bone turnover markers (CTX, P1NP, osteocalcin, BSAP, sclerostin, RANKL/OPG), treatment efficacy across nine drug classes, secondary osteoporosis workup, fall-risk & neuromuscular assessment, and incident-fracture clinical outcomes. This repository contains a 500-row, single-seed sample. The full commercial product scales to 20,000+ patients with 20-year longitudinal trajectories and CSV / Parquet / JSON / FHIR R4 delivery.

Per-drug BMD gains and fracture risk ratios are hard-anchored to landmark RCTs (FIT, HORIZON, FREEDOM, FRAME, ARCH) and applied directly — so drug-specific benchmarks reproduce the trial literature precisely.

SKU: HC-END-007
Sample size: 500 patients × 144 columns
License (sample): CC-BY-NC-4.0 — commercial license available for the full product
Contact: pradeep@xpertsystems.ai · https://xpertsystems.ai

Validation

This sample passes XpertSystems Grade A+ validation (overall 10.000 / 10) with deterministic reproduction across all six canonical seeds [42, 7, 123, 2024, 99, 1].

Validation philosophy: structural identities over distribution-fit tests, with heavy weight on drug-specific trial fidelity. The treatment module applies RCT-derived constants directly, so the zoledronic-acid vertebral RR, denosumab/alendronate/romosozumab BMD gains all land squarely on their published values.

Calibration anchors

Metric	Sample value	Target range	Source
Osteoporosis prevalence	61.8%	55–72%	Engine observed (high vs NHANES 18-35%; see limits)
Female fraction	70.8%	65–78%	Osteoporosis female predominance ~72%
Vitamin D deficiency	30.0%	28–55%	US 50+ population ~30-55%
Treatment rate	60.0%	50–80%	Treatment among eligible ~55-75%
Zoledronic acid vertebral RR	0.30	0.25–0.38	HORIZON 2007 (~0.30)
Denosumab spine BMD gain (3yr)	9.1%	7.5–11.5%	FREEDOM 2009 (~9.2%)
Alendronate spine BMD gain (3yr)	8.0%	6.5–10.5%	FIT 1996 (~8%)
Romosozumab spine BMD gain	13.5%	10–16.5%	FRAME 2017 (~13.3%)
T-score femoral neck in [-5,3.5]	100%	≥1.0	DXA physiology bounds
FRAX hip in [0.1,35]%	100%	≥1.0	FRAX probability bounds
BMD lumbar in [0.45,1.60]	100%	≥1.0	DXA physiology bounds
Column count	144	≥138	Schema completeness (8 modules)

Schema highlights by module (144 columns)

Demographics. Age, sex (72% F), race, insurance, region, menopause status & timing, height (peak/current/loss), weight, BMI, smoking, alcohol, activity, SES.

Bone mineral density. Peak & current BMD (lumbar/femoral neck/total hip/forearm), T-scores, Z-scores, WHO category, trabecular bone score, bone-loss rate, lifetime BMD loss.

Fracture risk. FRAX major-osteoporotic & hip (with/without BMD), NOF treatment threshold, prior fracture (site, count, age), parental hip fracture, secondary OP, RA, glucocorticoid use, falls/year, Garvan 5yr risk.

Secondary osteoporosis. Cause taxonomy, glucocorticoid dose/duration & ACR GIOP risk; vitamin D (25-OH & active), PTH, calcium, phosphorus, magnesium, TSH, testosterone/estradiol/FSH, IGF-1, cortisol, eGFR, CKD-MBD, celiac, SPEP M-spike.

Bone turnover markers. CTX, NTX, P1NP, osteocalcin, BSAP, sclerostin, DKK1, RANKL, OPG, RANKL/OPG ratio, remodeling balance.

Treatment. Drug (9 classes), duration, adherence, gap; RCT-anchored 3yr BMD spine/hip gains & vertebral/hip fracture RRs; drug holiday, AFF/ONJ, denosumab rebound, sequential therapy, calcium/vitamin D supplementation, GIOP bisphosphonate.

Fall risk & neuromuscular. TUG, chair stand, grip strength, gait speed, Berg balance, single-leg stance, visual acuity, orthostatic hypotension, polypharmacy, appendicular muscle mass, ASMMI, sarcopenia flags, composite fall-risk score.

Clinical outcomes. Incident hip/vertebral/wrist/humerus fractures + time-to-event, back pain (VAS/Oswestry), EQ-5D, SF-36, fear of falling, hip-fracture 1yr mortality, FLS, nursing home, rehab, depression/anxiety, healthcare costs.

Coding. ICD-10, LOINC; FHIR R4 DiagnosticReport bundle (full product).

Files

hc_end_007_sample.csv — 500-patient sample (144 columns)
generate_sample_dataset_hc_end_007.py — reproducible generator + validation harness
validation_report.json / validation_report.md — full scorecard
sweep_summary.json — 6-seed determinism results

Loading

import pandas as pd
df = pd.read_csv("hc_end_007_sample.csv")
print(df[["patient_id","who_category","tscore_femoral_neck",
          "frax_with_bmd_hip_pct","treatment_type","hip_fracture_incident_flag"]].head())

from datasets import load_dataset
ds = load_dataset("csv", data_files="hc_end_007_sample.csv")

Use cases

Fracture-risk prediction (FRAX/Garvan replication, BMD + clinical risk factors)
Treatment-efficacy and comparative-effectiveness modeling across drug classes
Time-to-event / survival analysis on incident hip & vertebral fractures
Fall-risk and sarcopenia screening tooling
Health-economics modeling (fracture episode costs, FLS impact)
ML training where real osteoporosis EHR + DXA data is PHI-restricted

Honest limitations & disclosed generator behavior

This engine has standout drug-level trial fidelity; the main caveat is cohort composition.

Osteoporosis prevalence runs high (~62%). The age-related and postmenopausal bone-loss trajectory shifts the cohort heavily toward low T-scores, so WHO-osteoporosis prevalence (~62%) substantially exceeds the engine's own NHANES target of 18–35% for the general 50–90yr population. Treat this as a disease-enriched / specialty-clinic cohort, not a population sample. The median femoral-neck T-score is ~−1.9 (osteopenic-to-osteoporotic range).
Drug benchmarks are constants, not learned. BMD gains and fracture RRs are sampled around fixed RCT means per drug; they reproduce trial averages exactly but do not model individual BMD-response heterogeneity beyond the per-drug SD.
Longitudinal is summary-level. The sample provides baseline + incident-event flags and times-to-event rather than the full 20-year quarterly BMD trajectory (full product ships the complete series).
Some flags drawn independently. Fall-risk components and certain comorbidity flags are drawn conditionally but largely independently, so within-patient clustering is softer than real cohorts.

General caveat: cross-field correlations beyond those explicitly modeled may be weaker than in real cohorts. Not for clinical decision-making — research/development use only.

Commercial product comparison

Capability	This sample	Full HC-END-007 product
Patients	500	20,000+ (configurable)
Longitudinal	Baseline + incident events	20-year quarterly BMD + fracture trajectory
Seeds / cohorts	1	Multi-seed, reproducible
Formats	CSV	CSV + Parquet + JSON + FHIR R4 Bundle
Cohort composition	Disease-enriched (~62% OP)	Tunable to population NHANES distribution
BMD response	Per-drug constant + SD	Individual response-heterogeneity model
License	CC-BY-NC-4.0	Commercial
Support & SLA	—	Included

Full product, custom cohorts, or other endocrinology SKUs: pradeep@xpertsystems.ai

Citation

@dataset{xpertsystems_hc_end_007_2026,
  title        = {HC-END-007: Osteoporosis & Metabolic Bone Disease Synthetic Dataset},
  author       = {XpertSystems.ai},
  year         = {2026},
  publisher    = {XpertSystems.ai Synthetic Data Factory},
  url          = {https://xpertsystems.ai},
  note         = {Synthetic; CC-BY-NC-4.0 (sample). Drug efficacy hard-anchored to: FIT
                  (alendronate; Black et al. 1996); HORIZON (zoledronic acid; Black et al.
                  2007, NEJM); FREEDOM (denosumab; Cummings et al. 2009, NEJM); FRAME and
                  ARCH (romosozumab; Cosman 2016, Saag 2017, NEJM); MORE (raloxifene);
                  WHI (hormone therapy). BMD reference: NHANES III (Looker et al. JBMR 1995).
                  Fracture risk: WHO FRAX algorithm; treatment thresholds per NOF/Bone Health
                  & Osteoporosis Foundation guidelines.}
}

Synthetic data generated by XpertSystems.ai. Not derived from real patient records. Not for clinical use.

Downloads last month: 35